Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

BeiGene (6160 HK): Brukinsa Growth Momentum Lifts 2025, 2026 Guidance Announced

BeOne (6160 HK): Shares Are Breaking Into New Highs. Should You Buy?

BeiGene (6160 HK): Brukinsa Extend Lead in US, Robust Pipeline, Positive Guidance Revision

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/beone-medicines-ltd" target="_blank" data-smartkarma-citation="entities:27352:1" rel="noopener">BeOne Medicines (6160 HK)</a> announced 1Q26 results, with revenue of $1.5B, up 35% YoY, driven by 38% revenue growth of Brukinsa. Both adjusted operating and net incomes recorded triple-digit growth.</li>
<li>BeOne has raised 2026 revenue guidance range by $100M to reflect Brukinsa’s leadership position in the U.S. and continued global expansion in both Europe and rest of world markets.</li>
<li>BeOne has established its innovation prowess, which lends visibility beyond Brukinsa. 2026 is a pivotal year with anticipated new approvals, label expansions, and late-stage trial data readouts.</li>
</ul>



BeOne Medicines (6160 HK) announced 1Q26 results, with revenue of $1.5B, up 35% YoY, driven by 38% revenue growth of Brukinsa. Both adjusted operating and net incomes recorded triple-digit growth.
BeOne has raised 2026 revenue guidance range by $100M to reflect Brukinsa’s leadership position in the U.S. and continued global expansion in both Europe and rest of world markets.
BeOne has established its innovation prowess, which lends visibility beyond Brukinsa. 2026 is a pivotal year with anticipated new approvals, label expansions, and late-stage trial data readouts.


BeOne Medicines (6160 HK): 好調な第1四半期決算を受け、カタリストの多い通期業績見通しを引き上げ